Rare diseases
Investigational molecules
Locations
Back to Italy22 clinical trials in Cefalu', Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)ItalyOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
ItalySafety and Feasibility of Home Use On-Body Injection System for Subcutaneous Ocrelizumab in Adults with Multiple Sclerosis
ItalyStudy of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks
ItalyStudy on ITI-1284 for Treating Psychosis in Alzheimer's Patients
ItalyStudy of BCG Vaccine and Sodium Chloride for Patients with Radiologically Isolated Syndrome (RIS)
ItalyLong-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis
ItalyStudy on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia
ItalyA Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease
ItalyStudy Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
ItalyStudy on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis
ItalyItalyThe busiest research cities in the country
What the registry says about research in the country
Comprehensive studies focusing on various forms of Multiple Sclerosis (MS), including relapsing-remitting and primary progressive types. Research aims to evaluate new therapeutic approaches and long-term treatment effectiveness.
Multiple ongoing trials examining innovative treatments like ABP 692, ocrelizumab, and LY3541860.
Groundbreaking research investigating treatments for Early Alzheimer's Disease and mild cognitive impairment. Studies focus on evaluating new compounds and their effects on disease progression.
Clinical trials examining promising compounds like BAN2401 and GSK4527226 for early intervention.
Diverse studies examining various neurological conditions, including Myasthenia Gravis and MOG antibody-associated disease. Research focuses on innovative treatment approaches.
Investigations include rozanolixizumab for MOGAD and telitacicept for generalized Myasthenia Gravis.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
